Vascular Development and Vessel Remodelling. Vittorio Pengo, Fabio Barbero,Alessandra Biasiolo, Cinzia Pegoraro, Franco Noventa 1,S.
|
|
- Andrea King
- 6 years ago
- Views:
Transcription
1 Schattauer GmbH, Stuttgart Vascular Development and Vessel Remodelling Prevention of thromboembolism in patients with mitral stenosis and associated atrial fibrillation: effectiveness of low intensity (INR target 2) oral anticoagulant treatment Vittorio Pengo, Fabio Barbero,Alessandra Biasiolo, Cinzia Pegoraro, Franco Noventa 1,S.Iliceto Clinical Cardiology,Thrombosis Centre and 1 5th Clinical Medicine, University of Padova, Padova, Italy Summary Mitral stenosis (MS) in association with atrial fibrillation (AF) is a clinical condition at high risk for systemic thromboembolism. Although oral anticoagulants greatly reduce the incidence of thromboembolism in these patients, the optimal intensity of treatment has never been tested in specific clinical trials, and current recommendations are derived from studies of nonrheumatic AF. In this study we tested the effectiveness of two different intensities. The study design was carried out as an open randomized prospective study in an anticoagulation clinic. We randomized 103 patients with MS and AF to a low (target INR = 2) or moderate (target INR = 3) anticoagulation regimen. The primary end points were systemic thromboembolism, major bleeding and vascular death. During a mean follow-up of 4.5 years, 1 systemic embolism occurred in the low intensity group (0.41 per 100 pt/yrs, Keywords Anticoagulants, mitral valve, atrial fibrillation CI ), and 1 minor stroke occurred in the moderate intensity group (0.40 per 100 pt/yrs, CI ; p = ns). Major bleeding occurred in 8 patients, with 3 in the low intensity (1.25 per 100 pt/yrs) and 5 in the moderate intensity group (2.0 per 100 pt/yrs, Incidence Rate Ratio 0.6, CI ; p = ns). Total events (systemic embolism, major bleeding and vascular death) occurred in 7 low intensity patients and 8 moderate intensity patients. As expected, minor bleeding was more frequent in the moderate intensity group of patients, who actually had more intense treatment and required closer monitoring of oral anticoagulant treatment. These data suggest that low intensity anticoagulation, as performed in an anticoagulation clinic, is effective and safe in high risk patients with MS and AF. Thromb Haemost 2003; 89: Introduction Mitral stenosis (MS) is a clinical condition frequently associated with systemic thromboembolism (TE) (1), the rate of which in untreated patients varies from 9-14% (2) to 25% (3). Impaired blood influx into the left ventricle through a restricted mitral valve orifice and atrial fibrillation (AF) are the main pathogenic causes of thrombus formation in the left atrium (4). Although several trials suggested the utility of oral anticoagulants in preventing systemic thromboembolism in rheumatic valve disease, none has been adequately controlled (3, 5, 6). Nevertheless, oral anticoagulation has become the treatment of choice in the absence of further prospective randomized clinical trials. Initially, the recommended intensity of treatment was aimed at maintaining the International Normalized Ratio (INR) at INR (7) or even higher (8); more recently, the British Society of Hematology (9) and the American College of Chest Physicians (10) recommended a lower intensity treatment aimed Correspondence to: Vittorio Pengo Clinica Cardiologica, Centro Trombosi Università di Padova, Ospedale Ex Busonera via Gattamelata 64 I Padova, Italy Tel.: , Fax vittorio.pengo@unipd.it Received September 11, 2002 Accepted after revision January 27, 2003
2 Anticoagulants in mitral stenosis 761 at maintaining the INR between 2.0 and 3.0. However, these recommendations were not derived from specific studies but rather from extrapolation of the results of large randomized studies in patients with nonvalvular atrial fibrillation. These studies have reported three different therapeutic INR ranges to be effective for stroke prevention: (11), (12), and (13). Moreover, in a group of patients who underwent tissue valve replacement, a range of 2.0 to 2.25 was also effective in preventing thromboembolism (14). Given that a broad range of INR values appears effective in related clinical settings and that the intensity of treatment in patients with MS has never been properly assessed, we prospectively evaluated the effectiveness and safety of two regimens of oral anticoagulant treatment, i.e. low-intensity (target INR = 2) and moderate intensity (target INR = 3). Materials and methods This randomized open-labelled study was initiated in 1991 after approval by local health institutions. Informed consent was obtained from each patient. Patients Patients considered for this study were diagnosed by means of doppler echocardiography or angiography (15, 16) and mitral valve area was calculated according to the pressure half-time method (17). Mitral stenosis was considered mild, moderate and severe when mitral valve area was 2 cm 2, <2 cm 2 and >1 cm 2, and 1 cm 2, respectively. Mitral regurgitation was graded with the use of the color Doppler-jet area method (18). Exclusion criteria comprised the following: a) inability to obtain informed consent; b) poor compliance to oral anticoagulant treatment; c) previous major bleeding (19); d) heart failure (New York Heart Association class III-IV); h) antiplatelet therapy if not suspended 1 week before; i) life expectancy of less than 12 months; j) planned cardioversion. Randomization and follow-up Enrolled patients were randomly allocated into 2 groups: Group L received oral anticoagulants (warfarin or acenocoumalol) to maintain the INR at a target value of 2.0 (low intensity treatment), and Group M to maintain the INR at a target value of 3.0 (moderate intensity treatment). Patients were randomized in blocks of 10 using a computer program. Surveillance of oral anticoagulant treatment was performed following the guidelines provided by the Italian Federation of Anticoagulation Clinics (20). Patients were considered to have dropped out of the study if therapy was interrupted for more than 1 month, if an exclusion criterion or an indication for standard oral anticoagulant treatment arose during the study, or if the patient was transferred to another center. Patients lost to follow-up were censored at the time of their last study visit. Events Primary outcome events were ischemic stroke, defined as sudden neurological deficit lasting >24 h in the absence of cerebral hemorrhage at neuroimaging; peripheral or visceral embolism, defined as the occurrence of acute ischemia documented by angiography or surgery in the absence of atherosclerotic occlusive disease; cerebral hemorrhage, documented at neuroimaging; major bleeding as previously defined (19); and vascular death, defined as a death in which a nonvascular cause was not clearly documented. The INR was defined as temporally related to an outcome event if it was measured at the time of the event or during the preceding 8 days. Secondary outcome events were acute myocardial infarction characterized by typical chest pain, electrocardiogram changes and significant increase in cardiac enzymes, and total mortality. Primary and secondary end-points were evaluated by a neurologist and a cardiologist unaware of the treatment group. The method of Rosendaal et al. (21) was used to evaluate the achieved intensity of anticoagulation in the two groups. Statistical analysis Patients with MS and AF on oral anticoagulants have a rate of thromboembolism as low as 0.7%/yr (22); considering the low number of patients with this clinical condition, a classical equivalence study exploring the efficacy and safety of two intensity treatments would require enrolment of a large number of subjects. To explore the efficacy of two different intensities of oral anticoagulant treatment we randomly assigned these patients to two treatment groups (low or medium intensity anticoagulation) for a cumulative follow-up period of at least 200 pt/yrs per group with the objective of describing the rate of thromboembolism in comparison to data obtained in randomized trials on nonrheumatic atrial fibrillation. The incidence of thromboembolic and hemorrhagic events was considered stable with time and therefore event rates were expressed as incidence rate and relative (Poisson) confidence intervals; event rates were then compared by means of incidence rate ratios (23). Mean INR values and mean weekly warfarin dosage in the two groups were compared by Student s t test for continuous variables. Results From March 1991 to March 1997, 135 patients referred to Padova s Thrombosis Centre with MS were assessed for eligibility. Twenty-eight were excluded for the following reasons: unavailability for regular follow-up (n = 13); previous major bleeding while on oral anticoagulant treatment (n = 5); congestive heart failure (n = 5); programmed DC electric cardioversion (n = 4); life expectancy of less than 12 months (n = 1). The remaining 107 patients were randomly assigned to low intensity (group L, target INR = 2) anticoagulation treatment (n = 52)
3 762 Pengo, et al. Table 1: Characteristics of patients with mitral stenosis at randomization Principal outcome events No difference in primary outcome events was evident, as 2 episodes of systemic thromboembolism were recorded, consisting of 1 peripheral embolism in group L (0.4 per 100 pt/yrs, CI ) and 1 minor stroke in group M (0.4 per 100 pt/yrs, CI ; p = ns); the related INR were 2.4 and 2.1, respectively. Figure 1 shows incidence rates and corresponding confidence intervals in the two arms in comparison with results of 5 randomised clinical trials on nonrheumatic atrial fibrillation. Major bleeding occurred in 8 patients, 3 in group L (1.25 per 100 pt/yrs, CI ) and 5 in group M (2.0 per 100 pt/yrs, CI ). The incidence rate ratio of major bleeding was 0.6 (CI , p = ns). There were 3 cases of intracranial bleeding, all in group M (two of which were fatal); the related INRs at presentation were 2.6, 3.9 and 3.5. Vascular death occurred in 5 patients, 3 in group L (1.25 per 100 pt/yrs, CI ) and 2 in group M (0.8 per 100 pt/yrs, CI ; p = ns). Total outcome events occurred in 7 patients in group L and 8 in group M. Other events One patient in group L suffered an acute myocardial infarction and subsequently underwent mitral valve substitution and aortocoronary by-pass surgery. Five patients, 3 in group L (1,25 per 100 pt/yrs) and 2 in group M (0.8 per 100 pt/yrs), died of nonvascular death. Twenty-seven minor bleeding events were recorded in group L (11.5 per 100 pt/yrs) and 77 in group M (31.2 per 100 pt/yrs); the incidence rate ratio was statistically significant (0.35, CI ; p <0.001). or to the moderate intensity treatment (group M, target INR = 3, n = 55). The study was terminated in March Patients showed comparable baseline characteristics (Table 1). Total follow-up was 485 years (240 for group L and 245 for group M) with a mean follow-up of 4.5 years. Twelve patients dropped out; of these, 6 patients (3 in each group) were followed in other centers, 4 patients (3 in group L and 1 in group M) suspended oral anticoagulant treatment after effective non programmed cardioversion, 1 patient in group L dropped out due to a relative contraindication to treatment (acute pancreatitis), 1 patient in group M dropped out after the target INR was reduced for recurrent metrorrhagia. Sixteen patients (7 in group L and 9 in group M) terminated the study prior to surgical substitution of a mitral heart valve with a mechanical prosthesis. No patients were lost to follow-up. Quality of oral anticoagulant treatment Patients in group L had 3302 INR determinations and dose prescriptions (as a mean, one every 26 days) while patients in group M had 4177 INR determinations and dose prescriptions (as a mean, one every 21 days). Fig. 2 shows that the achieved intensity of treatment in the two groups was actually different. Patients in the target 2 group spent 74% of the time at an INR between 1.5 and 2.5, while patients in the target 3 group spent Figure 1: Incidence rates of systemic thromboembolism and corresponding confidence intervals in the two studied arms (Target 2,Target 3) in comparison with results of 5 randomised clinical trials on nonrheumatic atrial fibrillation.the BAATAF and SPINAF studies did not consider peripheral thromboembolism as primary end-point.
4 Anticoagulants in mitral stenosis 763 Figure 2: Percent of patient-time among the INR categories in the low intensity (target 2) and in the moderate intensity (target 3) groups. 51% of the time at an INR between 2.5 and 3.5.The mean INR value in group L was 2.14 ± 0.64 SD (median INR = 2.01); this value was significantly lower than that found in group M (mean INR value 2.76 ± 0.93, p <0.0001; median INR = 2.66). The mean weekly warfarin dosage was accordingly lower in group L (25.5 ± 8.9 SD mg/week) than in group M (28.4 ± 11.2 SD mg/week, p <0.0001). Discussion Mitral stenosis is a clinical condition associated with high risk of systemic embolism, which is the presenting feature of the disease in 12.4% of cases (2). The incidence of systemic emboli is seven times greater with the development of atrial fibrillation (24), with a prevalence of systemic emboli at autopsy of 41% (25). Early studies demonstrated that oral anticoagulant treatment dramatically reduces systemic embolism in patients with mitral valve diseases (26). Although never evaluated in a randomised trial, there was little doubt regarding the effectiveness of oral anticoagulation in reducing systemic embolism in these patients. Non randomised studies, in fact, showed a decrease in systemic embolism from 9.8% to 3.4% per patient-year (24) in the 1960s; the incidence of systemic thromboembolism further decreased to 0.8% per patient year in a series of 217 patients treated over a 9.5-year period (3). This figure is consistent with that found in the present study (0.4% per patient year) and with those reported in both retrospective (0.7%) (22) and randomized prospective studies of patients with atrial fibrillation (0.41% and 0.90%, respectively) (13, 27) who are at lower risk. In a recent multicenter inception cohort study of patients with atrial fibrillation treated with oral anticoagulants at an INR range of 2.0 to 3.0 or 2.0 to 3.5, the rate of systemic thromboembolism was 0.3% per patient year (28). The incidence of thromboembolism rose to 3.7% when ineffective low doses warfarin were used (29). Therefore, in the present study, the rate of systemic thromboembolism in high risk patients treated with low intensity oral anticoagulant treatment should be considered satisfactory and does not differ from that obtained in the moderate intensity group. On the other hand all 3 episodes of cerebral bleeding occurred in the moderate intensity group of patients, who spent a longer time at high intensity anticoagulation. We know that the bleeding risk is much higher for INR values above 5.0, and significantly increases even at INR values above 3.0 (19). A further advantage of low intensity anticoagulant treatment in these patients is the lower frequency of INR determinations and lower rate of minor bleeding events, both of which might contribute to improving the patients quality of life and compliance. The principal limitation of the present study is that the sample size was not calculated to allow evaluation of the equivalence between the two therapeutic regimens. Nevertheless, the cumulative follow-up was sufficiently long to postulate near equivalence in terms of systemic thromboembolism. In conclusion a low intensity of oral anticoagulant treatment (target INR = 2) might be preferred in patients with MS and AF as incidence rates and confidence intervals for thromboembolic complications are the same as those obtained with a moderate intensity and in line with those obtained in clinical trials dealing with a condition at much lower risk. Moreover, the lower number of major bleeding events and less frequent controls appear to favour a less intense treatment. We do not know, however, if these results can be extrapolated to routine care for anticoagulated patients, as they were obtained in the setting of an anticoagulation clinic within a cardiology department. Abbreviations MS = Mitral Stenosis AF = Atrial Fibrillation TE = Tromboembolism INR = International Normalized Ratio
5 764 Pengo, et al. References 1. Chesebro JH, Adams PC, Fuster V. Antithrombotic therapy in patients with valvular heart disease and prosthetic heart valves. JACC 1986; 8: 41B-56B. 2. Wood P. Disease of the heart and circulation. Philadelphia PA: JB Lippincott, Fleming HA, Bailey SM. Mitral valve disease, systemic embolism and anticoagulants. Postgrad Med 1971; 47: Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingam Study. Neurology 1978; 28: Adams GF, Merret JD, Hutchinson WM, Pollack AM. Cerebral embolism and mitral stenosis: survival with and without anticoagulants. J Neurol Neurosurg Psychiatry 1974; 37: Neilson GH, Galea EG, Hassak KF. Thromboembolic complication of mitral valve disease. Aust NZ J Med 1978; 8: Loeliger EA, Poller L, Samama M, Thompson JM, Van den Besselaar AMHP, Vermylen J, Verstraete M. Questions and answers on prothrombin time standardization in oral anticoagulant control. Thromb Haemost 1985; 54: Van den Besselaar AMHP, Van der Meer FJM, Gerrits-Drabbe CW. Therapeutic control of oral anticoagulant treatment in the Netherlands. Am J Clin Pathol 1988; 90: Guidelines on oral anticoagulation: second edition. J Clin Pathol 1990; 43: Levine HJ, Pauker SG, Salzman EW, Eckman MH. Antithrombotic therapy in valvular heart disease. Chest 1992; 102: 435S-44S. 11. Petersen P, Godtfredsen J, Boysen G, Andersen ED, Andersen B. Placebo controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complication in chronic atrial fibrillation. The Copenhagen AFASAK Study. Lancet 1989; 1: Stroke Prevention in Atrial Fibrillation Investigators Stroke Prevention in Atrial Fibrillation Study: final results. Circulation 1991; 84: The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigation (BAATAF). The effect of low-dose warfarin on the risk of stroke in patients with norheumatic atrial fibrillation. N Engl J Med 1990; 323: Turpie AGG, Gunsten J, Hirsh J, Nelson H, Gent M. Randomised comparison of two intensities of anticoagulant therapy after tissue heart valve replacement. Lancet 1988; 1: Nishimura RA, Miller FA, Callahan MJ, Benassi RC, Seward JB, Tajik AJ. Doppler echocardiography: theory, instrumentation technique and application. Mayo Clin Proc 1985; 60: Khandheria BK, Tajik AJ, Reeder GS, Callahan MJ, Nishimura RA, Miller FA, Seward JB. Doppler color flow imaging: a new technique for visualization of the blood flow jet in mitral stenosis. Mayo Clin Proc 1986; 61: Hatle L, Angelsen B, Tromsdal A. Noninvasive assessment of atrioventricular pressure half-time by Doppler ultrasound. Circulation. 1979; 60: Roldan CA, Shively BK, Crawford MH. An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus. N Engl J Med 1996; 335: Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S on the behalf of the Italian Study on Complications of Oral Anticoagulant Therapy. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996; 348: Italian Federation of Anticoagulation Clinics. A guide to oral anticoagulant treatment. Sergio Coccheri Editor. Karger, Basel. Haemostasis 1998; 28 (S1): Rosendaal FR, Cannegieter SC, Vandermeer FJM, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: Roy D, Marchand E, Gagne P, Chabot M, Cartier R. Usefulness of anticoagulant therapy in the prevention of embolic complications of atrial fibrillation. Am Heart J 1986; 112; Sahai H, Kurshid A. Statistics in epidemiology: methods, techniques and applications. CRC press Szekely P. Systemic embolism and anticoagulant prophylaxis in rheumatic heart disease. BMJ 1964; 1: Hinton RC, Kistler JP, Fallon JT, Friedlich AL, Fisher CM. Influence of etiology of atrial fibrillation on incidence of systemic embolism. Am J Cardiol 1977; 40: Owren PA.The result of anticoagulant therapy in Norway. Arch Int Med 1963; 111: Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, Krause-Steinraue H, Kurtzke JF, Nazarian SM, Radford MJ, Rickles FR, Shabetal R, Deykin D. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992; 327: Pengo V, Legnani C, Noventa F, Palareti G. Oral anticoagulant therapy inpatients with nonrheumatic atrial fibrillation and risk of bleeding. Thromb Haemost 2001; 85: Pengo V, Zasso A, Barbero F, Banzato A, Nante G, Parissenti L, John N, Noventa F, Dalla Volta S. Effectiveness of fixed mini-dose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation. Am J Cardiol 1998; 82:
The randomized study of efficiency and safety of antithrombotic therapy in
.. [ ] 18 150 160 mg/d 2 mg/d INR 2.0 3.0( 75 INR 1.6 2.5) 704 369 335 420 59.7% 63.3 9.9 19 2 24 2.7% 6.0% P =0.03 OR 0.44 95% CI 0.198 0.960 56% 62% 1.8% 4.6% P =0.04 OR 0.38 95% CI 0.147 0.977 52% 10.6%
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION Optimal Level of Oral Anticoagulant Therapy for the Prevention of Arterial Thrombosis in Patients With Mechanical Heart Valve Prostheses, Atrial Fibrillation, or Myocardial Infarction
More informationAntithrombotic Therapy in Patients with Atrial Fibrillation
Antithrombotic Therapy in Patients with Atrial Fibrillation June Soo Kim, M.D., Ph.D. Department of Medicine Cardiac & Vascular Center, Samsung Medical Center Sungkyunkwan University School of Medicine
More informationMMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin?
MMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin? Daniel E. Singer, MD Massachusetts General Hospital Harvard Medical School 1 Speaker Disclosure Information DISCLOSURE
More informationEchocardiographic Predictors of Stroke in Patients With Atrial Fibrillation
ORIGINAL INVESTIGATION Echocardiographic Predictors of Stroke in Patients With Atrial Fibrillation A Prospective Study of 1066 Patients From 3 Clinical Trials Atrial Fibrillation Investigators: Atrial
More informationSubjects with nonrheumatic atrial fibrillation
1000 Risk Factors for Stroke and Other Embolic Events in Patients With Nonrheumatic Atrial Fibrillation Kenneth M. Flegel, MD, MSc, FACP, and James Hanley, PhD Factors associated with stroke and other
More informationJournal of the American College of Cardiology Vol. 44, No. 8, by the American College of Cardiology Foundation ISSN /04/$30.
Journal of the American College of Cardiology Vol. 44, No. 8, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.05.084
More informationBehavior of Prothrombin Time (INR) in Response to Warfarin Therapy in a Thai Population
Behavior of Prothrombin Time (INR) in Response to Warfarin Therapy in a Thai Population Sarana Boonbaichaiyapruck,MD, FACC* Pradit Panchavinnin,MD.** Taworn Suthichaiyakul,MD.*** Thanawat Benjanuwatra,MD.****
More informationWarfarin-associated intracerebral hemorrhage occurs with lower intensification of anticoagulation in Chinese
Neurol J Southeast Asia 2001; 6 : 107 111 ORIGINAL ARTICLES Warfarin-associated intracerebral hemorrhage occurs with lower intensification of anticoagulation in Chinese V Mok MRCP, KS Wong FRCP, *WWM Lam
More informationThe New England Journal of Medicine
AN ANALYSIS OF THE LOWEST EFFECTIVE INTENSITY OF PROPHYLACTIC ANTICOAGULATION FOR PATIENTS WITH NONRHEUMATIC ATRIAL FIBRILLATION ELAINE M. HYLEK, M.D., M.P.H., STEVEN J. SKATES, PH.D., MARY A. SHEEHAN,
More informationMaking Choices. Treatments to Prevent Stroke in Patients with Atrial Fibrillation. Physician s Manual
Making Choices Treatments to Prevent Stroke in Patients with Atrial Fibrillation Physician s Manual Table of Contents Purpose of the decision aid................................... 2 Purpose of this physician
More informationEvidence-based study on antithrombotic therapy in patients at risk of a stroke with paroxysmal atrial fibrillation
EXPERIMENTAL AND THERAPEUTIC MEDICINE 6: 413-418, 2013 Evidence-based study on antithrombotic therapy in patients at risk of a stroke with paroxysmal atrial fibrillation XINJUN CHEN 1*, RONGHUA WAN 2*,
More informationBleeding Risk Factors in Chronic Oral Anticoagulation With Acenocoumarol
American Journal of Hematology 63:192 196 (2000) Bleeding Risk Factors in Chronic Oral Anticoagulation With Acenocoumarol Patricia Casais, 1 * Analía Sánchez Luceros, 1 Susana Meschengieser, 1 Carlos Fondevila,
More informationIS THERE STILL A PLACE FOR VITAMINE K ANTAGONISTS?
IS THERE STILL A PLACE FOR VITAMINE K ANTAGONISTS? J.Y. LE HEUZEY Georges Pompidou Hospital, René Descartes University, Paris H E G P Munich, August 27, 2012 Disclosure Consultant / Conferences / Advisory
More informationKey Words: Prostheses Warfarin Stroke Bleeding.
Low-Intensity Oral Anticoagulant Plus Low-Dose Aspirin During the First Six Months Versus Standard-Intensity Oral Anticoagulant Therapy After Mechanical Heart Valve Replacement: A Pilot Study of Low-Intensity
More informationApixaban for stroke prevention in atrial fibrillation. August 2010
Apixaban for stroke prevention in atrial fibrillation August 2010 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationResults from RE-LY and RELY-ABLE
Results from RE-LY and RELY-ABLE Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in longterm stroke prevention EXECUTIVE SUMMARY Dabigatran etexilate (Pradaxa ) has shown a consistent
More informationNonvalvular atrial fibrillation is an important independent
Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation: A Meta-Analysis Robert G. Hart, MD; Oscar Benavente, MD; Ruth McBride, BS; and Lesly A. Pearce, MS Purpose: To characterize
More informationAPPENDIX A NORTH AMERICAN SYMPTOMATIC CAROTID ENDARTERECTOMY TRIAL
APPENDIX A Primary Findings From Selected Recent National Institute of Neurological Disorders and Stroke-Sponsored Clinical Trials That Have shaped Modern Stroke Prevention Philip B. Gorelick 178 NORTH
More informationDabigatran and Warfarin in Vitamin K Antagonist Naive and Experienced Cohorts With Atrial Fibrillation
Dabigatran and Warfarin in Vitamin K Antagonist Naive and Experienced Cohorts With Atrial Fibrillation Michael D. Ezekowitz, MBChB, DPhil, FRCP; Lars Wallentin, MD, PhD; Stuart J. Connolly, MD; Amit Parekh,
More informationIs Stroke Frequency Declining?
Is Stroke Frequency Declining? Etiologic Factors Clinical, Anatomic, Technique-related, and Device-specific Samir Kapadia, MD Professor of Medicine Section head, Interventional Cardiology Director, Cardiac
More informationTransient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction
Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction Doron Aronson MD, Gregory Telman MD, Fadel BahouthMD, Jonathan Lessick MD, DSc and Rema Bishara MD Department of Cardiology
More informationEarly Recurrent Embolism Associated with Nonvalvular Atrial Fibrillation: A Retrospective Study
Early Recurrent Embolism Associated with Nonvalvular Atrial Fibrillation: A Retrospective Study ROBERT G. HART, M.D.,* BRUCE M. COULL, M.D.,t AND DENISE HART, M.D.* SUMMARY Nonvalvular atrial fibrillation
More informationOcclusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France
Occlusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France LAA Occlusion Is there a real future? Background Protect AF Trial Other Studies CAP, ASAP, Prevail Left Atrial Appendage
More informationUnstable INR Has Implications for Healthcare Resource Use. Janssen Pharmaceuticals, Inc.
Unstable INR Has Implications for Healthcare Resource Use Janssen Pharmaceuticals, Inc. Stable INR is essential for effective anticoagulation treatment Achieving a stable international normalized ratio
More informationThe Risk of Hemorrhage Among Patients With Warfarin-Associated Coagulopathy
Journal of the American College of Cardiology Vol. 47, No. 4, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.09.058
More informationNeuroPI Case Study: Anticoagulant Therapy
Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination
More informationLa chiusura dell auricola per la prevenzione dello stroke nel paziente con FA
Antonio Manari U.O. Cardiologia Interventistica Azienda Ospedaliera Santa Maria Nuova Reggio Emilia Istituto di Ricovero e Cura a Carattere Scientifico La chiusura dell auricola per la prevenzione dello
More informationATRIAL FIBRILLATION HAS BEEN
CLINICAL CARDIOLOGY Preventing Stroke in Patients With Atrial Fibrillation Michael D. Ezekowitz, MBChB, PhD Jody A. Levine, BA ATRIAL FIBRILLATION HAS BEEN variously described as rebellious palpitations,
More informationDr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre
Dr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre Objectives To learn what s new in stroke care 2010-11 1) Acute stroke management Carotid artery stenting versus surgery for symptomatic
More informationMODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationGains and losses of warfarin therapy as performed in an anticoagulation clinic
Journal of Internal Medicine 2006; 259: 296 304 doi:10.1111/j.1365-2796.2005.01605.x Gains and losses of warfarin therapy as performed in an anticoagulation clinic A. M. NJAASTAD 1,U.ABILDGAARD 1 &J.F.LASSEN
More informationLeft Atrial Appendage Occlusion in the Era of Novel Anticoagulants
Left Atrial Appendage Occlusion in the Era of Novel Anticoagulants Saibal Kar, MD, FACC, FSCAI Professor of Medicine Director of Interventional Cardiac Research Heart Institute, Cedars-Sinai Medical Center,
More informationPage 1. Current Trends in the Management of Atrial Fibrillation: Left Atrial Appendage Occlusion. Atrial fibrillation: Scope of the problem
Current Trends in the Management of Atrial Fibrillation: Left Atrial Appendage Occlusion Benjamin A. D Souza, MD, FACC, FHRS Assistant Professor of Clinical Medicine Penn Presbyterian Medical Center Cardiac
More informationJournal of the American College of Cardiology Vol. 39, No. 9, by the American College of Cardiology Foundation ISSN /02/$22.
Journal of the American College of Cardiology Vol. 39, No. 9, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)01785-0
More information심방세동과최신항응고요법 RACE II AFFIRM 항응고치료는왜중요한가? Rhythm control. Rate control. Anticoagulation 남기병 서울아산병원내과. Clinical Impact of Atrial Fibrillation
소강당 심방세동과최신항응고요법 남기병 서울아산병원내과 Clinical Impact of Atrial Fibrillation QoL Hospitalization Stroke CHF Mortality 항응고치료는왜중요한가? Rhythm control Rate control Anticoagulation JACC Vol. 38, No. 4, 2001 AFFIRM RACE
More informationBridging anticoagulation definition
Bridging anticoagulation definition Giving a short-acting anticoagulant, consisting of sc LMWH or ev UFH for 10 to 12 day period during interruption of VKA therapy when the INR is not within therapeutic
More informationThe Journal of Thoracic and Cardiovascular Surgery
Accepted Manuscript Scylla versus Charybdis: the eternal dilemma continues Vivek Rao, MD, PhD PII: S0022-5223(18)32088-9 DOI: 10.1016/j.jtcvs.2018.07.092 Reference: YMTC 13320 To appear in: The Journal
More informationRecurrence risk after anticoagulant treatment of limited duration for late, second venous thromboembolism
ARTICLES Coagulation & its Disorders Recurrence risk after anticoagulant treatment of limited duration for late, second venous thromboembolism Tom van der Hulle, Melanie Tan, Paul L. den Exter, Mark J.G.
More informationDirect Oral Anticoagulant Use in Valvular Atrial Fibrillation
Direct Oral Anticoagulant Use in Valvular Atrial Fibrillation September 14, 2018 Nina Maguire, PharmD PGY1 Pharmacy Resident Seton Healthcare Family Christina.maguire@ascension.org ASCENSION TEXAS Direct
More informationMEDICAL POLICY SUBJECT: HOME PROTHROMBIN TIME MONITORING DEVICE. POLICY NUMBER: CATEGORY: Equipment/Supplies
MEDICAL POLICY SUBJECT: HOME PROTHROMBIN TIME 06/23/16, 6/22/17 PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial
More informationAntithrombotic therapy in patients with transient ischemic attack / stroke (acute phase <48h)
Antithrombotic therapy in patients with transient ischemic attack / stroke (acute phase
More informationEffect of Age on Stroke Prevention Therapy in Patients With Atrial Fibrillation The Atrial Fibrillation Investigators
Effect of Age on Stroke Prevention Therapy in Patients With Atrial Fibrillation The Atrial Fibrillation Investigators Carl van Walraven, MD, MSc, FRCPC; Robert G. Hart, MD; Stuart Connolly, MD, FRCPC;
More informationEvaluate Risk of Stroke & Bleeding in AF Patients
XV World Congress of Arrhythmias, Beijing, China - 17-20 September, 2015 Evaluate Risk of Stroke & Bleeding in AF Patients Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation
More informationLong-term bleeding events after mechanical aortic valve replacement in patients under the age of 60
Neth Heart J (2015) 23:111 115 DOI 10.1007/s12471-014-0626-9 ORIGINAL ARTICLE Long-term bleeding events after mechanical aortic valve replacement in patients under the age of 60 B. M. Swinkels & B. A.
More informationOcular Bleeding Related to Warfarin Anticoagulation in Patients with Mechanical Heart Valve and Atrial Fibrillation
The Journal of International Medical Research 2007; 35: 143 149 Ocular Bleeding Related to Warfarin Anticoagulation in Patients with Mechanical Heart Valve and Atrial Fibrillation I BIYIK 1, I MERCAN 2,
More informationAbstract. Introduction. imedpub Journals Doson Chua* Research Article. Cardiovascular Investigations: Open Access
Research Article imedpub Journals www.imedpub.com Cardiovascular Investigations: Open Access Vol. 2 No.1: 1 Use of Non-vitamin K Antagonist Oral Anticoagulants (NOAC) for Stroke Prevention in Patients
More informationWarfarin Management-Review
Warfarin Management-Review December 18, 2012 Elaine M. Hylek, MD, MPH Director, Thrombosis Clinic and Anticoagulation Service Boston University Medical Center Areas for Discussion Implications of time
More informationSubclinical AF: Implications of device based episodes
Subclinical AF: Implications of device based episodes Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC Disclosures: Clinical Trials and Consulting: Medtronic, Boston Scientific
More informationManagement of Anticoagulation during Device Implants; Coumadin to Novel Agents
Management of Anticoagulation during Device Implants; Coumadin to Novel Agents DR D Birnie Invited Faculty Core Curriculum Heart Rhythm Society May 8 th 2014 Disclosures Boehringer Ingleheim Research Support
More informationAssise de l AMCAR : 27Avril Anticoagulant treatment of AF
Assise de l AMCAR : 27Avril 2017 Cardiovascular morbidity and mortality and AF The Five Domains of Integrated AF Management FA: pathophysiology of thrombus formation Alteration of the atrial wall Myocytic
More informationAF stroke prevention in the Canadian context
AF stroke prevention in the Canadian context 5 th Annual State of the Heart Toronto, May 31, 2014 Andrew C.T. Ha, MD, MSc, FRCPC Cardiac Electrophysiology Toronto General Hospital, University Health Network
More informationAtrial Fibrillation Key Messages
Atrial Fibrillation Key Messages Dr Matthew Fay Westcliffe Medical Practice National Clinical Lead NHS Improvement www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Clinical Events
More informationThe oral anticoagulant warfarin sodium is one of the
Research Recherche Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial S. Jo-Anne Wilson, Philip S. Wells, Michael
More informationHospitalized Patients With Atrial Fibrillation and a High Risk of Stroke Are Not Being Provided With Adequate Anticoagulation
Journal of the American College of Cardiology Vol. 46, No. 9, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.06.077
More informationAtrial Fibrillation and Heart Failure: A Cause or a Consequence
Atrial Fibrillation and Heart Failure: A Cause or a Consequence Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania November
More informationSession Antiplatelet Therapy: How, Why and When? In patients with ischemic stroke/tia
GROUPE HOSPITALIER BICHAT-CLAUDE BERNARD PARIS DIDEROT UNIVERSITY - PARIS 7 Session Antiplatelet Therapy: How, Why and When? In patients with ischemic stroke/tia Pierre Amarenco INSERM U-698 and Denis
More informationUS FDA Approves Pradaxa (dabigatran etexilate) a breakthrough treatment for stroke risk reduction in non-valvular atrial fibrillation
Press Release For non-us Healthcare Media Boehringer Ingelheim GmbH Corporate Communications US FDA Approves Pradaxa (dabigatran etexilate) a breakthrough treatment for stroke risk reduction in non-valvular
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationTHE ABSENCE of a consensus
Lone Atrial Fibrillation in Elderly Persons A Marker for Cardiovascular Risk ORIGINAL INVESTIGATION Stephen L. Kopecky, MD; Bernard J. Gersh, MB, ChB, DPhil; Michael D. McGoon, MD; Chu-Pin Chu, BS; Duane
More informationDo Not Cite. Draft for Work Group Review.
Defect Free Acute Inpatient Ischemic Stroke Measure Bundle Measure Description Percentage of patients aged 18 years and older with a diagnosis of ischemic stroke OR transient ischemic attack who were admitted
More informationAspirin at the Intersection of Antiplatelet and Anticoagulant Therapy An Act of Commission?
Aspirin at the Intersection of Antiplatelet and Anticoagulant Therapy An Act of Commission? Ty J. Gluckman, MD, FACC, FAHA Medical Director, Center for Cardiovascular Analytics, Research and Data Science
More informationKeywords Oral anticoagulant therapy Elective surgery Perioperative management. Introduction
Intern Emerg Med (2007) 2:280 284 DOI 10.1007/s11739-007-0078-y ORIGINAL F. Baudo F. de Cataldo G. Mostarda A. Ghirarduzzi M. Molinatti V. Pengo D. Poli A. Tosetto E. Tiraferri E. Morra on behalf of Federazione
More informationWhen and how to combine antiplatelet agents and anticoagulant?
When and how to combine antiplatelet agents and anticoagulant? Christophe Beauloye, MD, PhD Head, Division of Cardiology Cliniques Universitaires Saint-Luc Brussels, Belgium Introduction Anticoagulation
More informationAspirin to Prevent Heart Attack and Stroke: What s the Right Dose?
The American Journal of Medicine (2006) 119, 198-202 REVIEW Aspirin to Prevent Heart Attack and Stroke: What s the Right Dose? James E. Dalen, MD, MPH Professor Emeritus, University of Arizona, Tucson
More informationNational Horizon Scanning Centre. Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation
Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation August 2008 This technology summary is based on information available at the time of
More informationAtrial Fibrillation. Alan Bell, MD, CCFP. Staff Physician, Humber River Regional Hospital. University of Toronto
Pearls in Thrombosis 1 Atrial Fibrillation Alan Bell, MD, CCFP Staff Physician, Humber River Regional Hospital Assistant tprofessor, Department tof Family and Community Mdii Medicine University of Toronto
More informationUsing the Variability of INRs to indicate the Risk of an Event in DAWN AC
Predicting Clinical Events Using the Variability of INRs to indicate the Risk of an Event in DAWN AC Syd Stewart, Managing Director, 4S DAWN Clinical Software Introduction It is widely agreed that neither
More informationThe Poor Long-Term Candidate for Warfarin: NOAC or Left Atrial Appendage Closure?
The Poor Long-Term Candidate for Warfarin: NOAC or Left Atrial Appendage Closure? Suneet Mittal, MD, FACC, FHRS Director, Electrophysiology Laboratory Valley Health System Ridgewood, NJ and New York, NY
More informationStratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto
Fibrillazione atriale: rischio tromboembolico, Venezia - 27/28 Novembre 2015 Stratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto Antonio Raviele, MD, FESC,
More informationKCS Congress: Impact through collaboration
Stroke Prevention in Atrial Fibrillation (SPAF) in Kenya Elijah N. Ogola FACC University of Nairobi Kenya Cardiac Society Annual Scientific Congress Mombasa 28 th June 1 st July 2017 KCS Congress: Impact
More informationAtrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases?
Atrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases? Nicolas Lellouche Fédération de Cardiologie Hôpital Henri Mondor Créteil Disclosure Statement of Financial Interest I currently
More informationStarting or Resuming Anticoagulation or Antiplatelet Therapy after ICH: A Neurology Perspective
Starting or Resuming Anticoagulation or Antiplatelet Therapy after ICH: A Neurology Perspective Cathy Sila MD George M Humphrey II Professor and Vice Chair of Neurology Director, Comprehensive Stroke Center
More informationPradaxa (dabigatran)
Pradaxa (dabigatran) Policy Number: 5.01.574 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Pradaxa
More informationTHE FRAMINGHAM STUDY Protocol for data set vr_soe_2009_m_0522 CRITERIA FOR EVENTS. 1. Cardiovascular Disease
THE FRAMINGHAM STUDY Protocol for data set vr_soe_2009_m_0522 CRITERIA FOR EVENTS 1. Cardiovascular Disease Cardiovascular disease is considered to have developed if there was a definite manifestation
More informationDental Management Considerations for Patients on Antithrombotic Therapy
Dental Management Considerations for Patients on Antithrombotic Therapy Warfarin and Antiplatelet Joel J. Napeñas DDS FDSRCS(Ed) Program Director General Practice Residency Program Department of Oral Medicine
More informationORIGINAL INVESTIGATION. Aharon Lubetsky, MD; Hagith Yonath, MD; David Olchovsky, MD; Ronen Loebstein, MD; Hillel Halkin, MD; David Ezra, MD
ORIGINAL INVESTIGATION Comparison of Oral vs Intravenous Phytonadione (Vitamin K 1 ) in Patients With Excessive Anticoagulation A Prospective Randomized Controlled Study Aharon Lubetsky, MD; Hagith Yonath,
More informationATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION
ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION Frederick Schaller, DO, MACOI,FACP Adjunct Clinical Professor Touro University Nevada DISCLOSURES I have no financial relationships
More informationThe Pendulum of Bridging Periprocedural Anticoagulant Therapy. Alan K. Jacobson, MD Cardiology Section Loma Linda VA Medical Center Loma Linda, CA
The Pendulum of Bridging Periprocedural Anticoagulant Therapy Alan K. Jacobson, MD Cardiology Section Loma Linda VA Medical Center Loma Linda, CA Disclosures Department of Veterans Affairs Industry Relationships:
More informationCite this article as: BMJ, doi: /bmj ae (published 10 October 2005) Self management of oral anticoagulation: randomised trial
Cite this article as: BMJ, doi:10.1136/bmj.38618.580903.ae (published 10 October 2005) Primary care Self management of oral anticoagulation: randomised trial D A Fitzmaurice, E T Murray, D McCahon, R Holder,
More informationW e have previously reported the results of a randomised
715 CARDIOVASCULAR MEDICINE Twenty year comparison of a mechanical heart valve with porcine bioprostheses H Oxenham, P Bloomfield, D J Wheatley, R J Lee, J Cunningham, R J Prescott, H C Miller... See end
More informationSubclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study
Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study Meagan Sullivan, PharmD PGY2 Cardiology Pharmacy Resident University of Chicago Medicine
More informationWHY? AF Increases Stroke Risk by Nearly 500% Disclosures. Terminology. Anticoagulation in Atrial Fibrillation: Why, What, When and for How Long
Anticoagulation in Atrial Fibrillation: Disclosures Why, What, When and for How Long Edward Kersh, MD, FACC Chief of Cardiology, St. Luke s Hospital, SF Clinical Professor of Medicine, UCSF CAPA, September
More informationAnticoagulation in Special populations. Ng Heng Joo Department of Haematology Singapore General Hospital
Anticoagulation in Special populations Ng Heng Joo Department of Haematology Singapore General Hospital roymatheson.com Objectives Safer anticoagulation for The elderly Chronic kidney disease Obese patients
More informationAtrial fibrillation Etiology and complications - A descriptive study
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-081.Volume 14, Issue 9 Ver. I (Sep. 2015), PP 115-119 www.iosrjournals.org Atrial fibrillation Etiology and complications
More informationLeft atrium appendage closure: A new technique for patients at high hemorrhagic risk
Left atrium appendage closure: A new technique for patients at high hemorrhagic risk Victoria Martin Yuste MD PhD ITC. Cardiology Department. Hospital Clinic. Barcelona SITE. Barcelona, Juin-9-2013 NON
More informationNONVALVULAR ATRIAL FIBRILlation
CLINICAL CARDIOLOGY Oral Anticoagulants vs Aspirin in Nonvalvular Atrial Fibrillation An Individual Patient Meta-analysis Carl van Walraven, MD, MSc, FRCPC Robert G. Hart, MD Daniel E. Singer, MD Andreas
More informationGestione peri-operatoria del paziente in terapia con antagonisti della vitamina K. B. Cosmi
Gestione peri-operatoria del paziente in terapia con antagonisti della vitamina K B. Cosmi Department of Angiology and Blood Coagulation S. Orsola-Malpighi University Hospital Bologna, Italy Overview Background
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationIn 1985, patients with nonvalvular atrial fibrillation (AF)
Comments, Opinions, and Reviews Atrial Fibrillation and Stroke Concepts and Controversies Robert G. Hart, MD; Jonathan L. Halperin, MD In 1985, patients with nonvalvular atrial fibrillation (AF) first
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY
More information6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia
6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac
More informationDespite improvements in valve design, stroke remains a serious
Surgery for Acquired Cardiovascular Disease Bando et al Early and late stroke after mitral valve replacement with a mechanical prosthesis: Risk factor analysis of a 24-year experience Ko Bando, MD a Junjiro
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationORIGINAL INVESTIGATION
Are the Results of Randomized Controlled Trials on Anticoagulation in With Atrial Fibrillation Generalizable to Clinical Practice? Andrew Evans, MRCP; Lalit Kalra, PhD, FRCP ORIGINAL INVESTIGATION Background:
More informationSindrome da anticorpi antifosfolipidi: clinica e terapia. Vittorio Pengo Clinical Cardiology, Padova, Italy
Sindrome da anticorpi antifosfolipidi: clinica e terapia Vittorio Pengo Clinical Cardiology, Padova, Italy Revised Classification Criteria for the Antiphospholipid Syndrome J Thromb Haemost 2006;4:295-306
More information